Full-Time

Senior Vice President Head of Inflammation & Immunology

Posted on 4/18/2026

Evotec

Evotec

1,001-5,000 employees

Global drug-discovery services via partnerships

No salary listed

Toulouse, France + 4 more

More locations: Germany | Brescia, Province of Brescia, Italy | Hamburg, Germany | Munich, Germany

In Person

Category
Biology & Biotech (2)
,
Requirements
  • PhD or equivalent in a relevant life science discipline
  • Minimum 15 years of experience, with solid strategical and technical understanding of the pharma R&D value chain and project deliverables with in-depth subject matter expertise in the Inflammation and Immunology space
  • Drug discovery experience from target ID to preclinical development (PDC) of at least 10 years, exposure to planning of clinical development and trials up to Proof of Concept (PoC) desirable
  • Proven track record in progressing discovery-stage programs and strategic collaborations
  • Experience in licensing, partnering, and external scientific representation
  • Strong network and credibility in the Inflammation & Immunology field
Responsibilities
  • Define and lead the scientific strategy for the therapeutic area, aligned with Evotec’s R&D and business objectives
  • Identify emerging opportunities based on scientific trends, competitive landscape, and unmet medical needs
  • Champion the therapeutic area’s vision internally and externally, ensuring scientific excellence and innovation
  • Own the R&D budget and ROI for the therapeutic area, including internal projects and strategic collaborations
  • Prioritize and oversee early-stage R&D initiatives, from target identification to preclinical development
  • Provide scientific leadership and collaborate with Operations, Key Account Management and Business Development to identify, shape, and convert RnD projects into partnerships
  • Represent Evotec’s expertise at customer events, scientific conferences, consortia, and in peer-reviewed publications
Desired Qualifications
  • Exposure to planning of clinical development and trials up to PoC’s

Evotec provides R&D services for drug discovery and development through strategic partnerships with pharma, biotech, and academic institutions, using platforms like iPSCs and machine learning. It conducts experiments and data analysis with iPSC-derived cellular models and AI/ML tools to identify and optimize drug candidates, often incorporating patient-derived materials for precision medicine, offering end-to-end discovery through clinical development under contract. The company differentiates itself with an integrated, data-driven, cell-based platform within a collaboration model and a focus on precision medicine, biologics, and gene therapy, with a strong US and European presence. Its goal is to bring new and better medicines to patients faster and at lower cost by making drug discovery and development more efficient through partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hamburg, Germany

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Just-Evotec Biologics revenue surged 104% in Q4 2025 with $650M Sandoz deal.
  • Horizon plan delivers €75M savings by 2027 via site optimization to 10 hubs.
  • New leaders like CFO Hinshelwood and CCO Khan drive commercial execution and partnerships.

What critics are saying

  • Horizon's 800 job cuts erode iPSC expertise, prompting Bristol Myers Squibb to switch providers.
  • Charles River Laboratories captures discovery clients amid Evotec's restructuring disruptions.
  • Schrödinger steals AI deals through faster in-silico cycles exploiting Evotec's negative EBITDA.

What makes Evotec unique

  • Proprietary platforms like PanOmics and iPSC-based modeling enable precision drug discovery.
  • Just-Evotec Biologics redefines affordable biologics manufacturing for partners.
  • AI-driven innovation integrates with wet-lab infrastructure across small molecules and cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 8th, 2026
Evotec delivers $67M cost savings and $650M Sandoz deal amid 1.1% revenue decline

Evotec SE reported mixed Q4 2025 results, with group revenue increasing 14.5% to €253.3 million, though full-year revenue fell 1.1% to €788.4 million. Adjusted group EBITDA for Q4 rose 103.6% to €58 million, whilst full-year EBITDA increased 81.9% to €41.1 million. The Just-Evotec Biologics segment achieved breakthrough growth, with Q4 revenue surging 104.2% and full-year revenue rising 39.8% to €259.4 million. The company secured a $650 million agreement with Sandoz and received multiple milestone payments from partnerships. Evotec delivered over €60 million in annualised cost savings and reduced capital expenditure by approximately 60%. The company is implementing its Horizon transformation programme, expected to deliver €75 million in structural savings by end-2027, though this involves closing four sites and eliminating 800 positions.

The Associated Press
Apr 7th, 2026
Evotec nominates Dieter Weinand as supervisory board chairman to drive commercial execution

Evotec has nominated Dieter Weinand as chairman of its supervisory board, pending approval at the 11 June 2026 annual general meeting. Weinand will succeed Prof. Dr Iris Löw-Friedrich, whose term concludes at the meeting as part of the company's planned succession process. Weinand brings over 30 years of pharmaceutical industry experience, having served as president, CEO and chairman of Bayer Pharmaceuticals and held senior roles at Pfizer, Bristol Myers Squibb and Sanofi. He currently serves on several biotech boards and will reduce his board commitments to comply with German corporate governance requirements. The appointment aims to strengthen Evotec's commercial execution, strategic partnerships and profitability as the Hamburg-based life sciences company continues its transformation. Weinand holds an MS in pharmacology and toxicology from Long Island University.

The Associated Press
Apr 1st, 2026
Evotec appoints Dr. Ashiq H. Khan as chief commercial officer with $7B+ deal track record

Evotec has appointed Dr Ashiq H Khan as chief commercial officer. Dr Khan brings over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, having closed more than $7 billion in agreements across US, EU and APAC markets. In his new role, Dr Khan will build a globally integrated commercial organisation aligned with Evotec's scientific capabilities. He most recently served as chief business officer at Iktos and previously held leadership roles at Proteros and Schrödinger. Evotec is a life science company specialising in drug discovery and development, integrating AI-driven innovation with advanced technologies. The company employs over 4,800 experts across Europe and the US.

The Associated Press
Mar 19th, 2026
Evotec receives $10M milestone from Bristol Myers Squibb for kidney cancer drug trial

Evotec has received a $10 million milestone payment from Bristol Myers Squibb following the initiation of a Phase 1 clinical study for BMS-986506, a protein degradation treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer. The study marks the first clinical milestone in the strategic protein degradation partnership between Evotec and Bristol Myers Squibb, which began in 2018 and was expanded in 2022. BMS-986506 is a cereblon E3 ligase modulator, or "molecular glue", developed using Evotec's multi-omics screening platform and AI-supported data analytics. The collaboration combines Evotec's PanOmics and PanHunter platforms with Bristol Myers Squibb's library of CELMoD agents to discover novel molecular glue degraders for oncology and other therapeutic areas.

Yahoo Finance
Mar 16th, 2026
Evotec unveils "Horizon" plan with $85M savings, 800 job cuts and 10-site footprint by 2028

Evotec has unveiled "Horizon", a transformation plan targeting €75 million in savings and guiding 2026 EBITDA to €0–40 million. The plan focuses on operational excellence, scientific leadership and commercial execution, building on earlier restructuring that delivered over €60 million in savings through end-2025. The company will reduce its global footprint from 14 sites to 10 over two years, resulting in approximately 800 position reductions. Evotec emphasises owned technology hubs in Toulouse and Verona as integrated discovery and preclinical development centres. Chief executive Christian Wojczewski said Evotec has upgraded commercial leadership and business development, with prospects increasing during the second half of 2025. The company previously streamlined its asset pipeline by 30% and reduced capital expenditure by 60% whilst strengthening its balance sheet.

INACTIVE